marketcap
Facebook
Twitter
Telegram
Report an ErrorQuarterly report 2024-Q2
added 08-09-2024
Neoleukin Therapeutics Financial Ratios 2011-2024 | NLTX
Annual Financial Ratios Neoleukin Therapeutics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
P/E |
0.1 | -0.7 | -2.3 | -20.5 | -4.6 | -1.7 | -6.1 | -9.0 | -6.1 | -3.8 | - | - | - |
P/S |
- | - | - | - | - | 2.1 | - | - | - | - | - | - | - |
EPS |
27.8 | -1.0 | -1.1 | -0.6 | -2.6 | -1.3 | -2.1 | -2.0 | -1.7 | -2.8 | -49.5 | -40.2 | - |
EV (Enterprise Value) |
-110 M | -33.8 M | 19.9 M | 509 M | 180 M | -19.3 M | 264 M | 311 M | 98 M | 82.3 M | -6.12 M | 51.4 M | - |
EBITDA per Share |
-106 | -0.97 | -1.08 | -0.879 | -0.847 | -1.34 | -2.14 | -1.96 | -1.72 | -2.57 | - | - | - |
EV/EBITDA |
0.2 | -10.3 | -7.6 | 0.8 | -5.0 | -8.1 | -4.3 | -3.5 | - | - | - | ||
PEG |
0.0 | 0.06 | 0.3 | -0.27 | 0.05 | -0.04 | 0.66 | 0.68 | -0.16 | 0.05 | - | - | - |
P/B |
0.0 | 0.4 | 1.0 | 3.6 | 2.2 | 0.7 | 3.1 | 2.3 | 1.2 | 2.5 | - | - | - |
P/CF |
-0.0 | -0.7 | -3.0 | -25.5 | -19.5 | -1.7 | -6.7 | -10.8 | -6.5 | -5.1 | - | - | - |
ROE % |
7.34 | 37.87 | -42.48 | -17.40 | -49.01 | -43.46 | -50.75 | -25.58 | -20.16 | -66.47 | - | - | - |
ROA % |
6.13 | -50.51 | -37.17 | -15.81 | -47.23 | -40.69 | -45.48 | -23.97 | -19.29 | -58.00 | - | - | - |
ROCE % |
-29.88 | 38.78 | -42.49 | -20.51 | -16.34 | -44.70 | -51.44 | -25.99 | -19.66 | -61.78 | - | - | - |
Current Ratio |
6.1 | 10.3 | 8.0 | 24.7 | 30.3 | 16.7 | 9.9 | 10.9 | 15.6 | 7.6 | - | - | - |
DSO |
- | - | - | - | - | 3.5 | - | - | - | - | - | - | - |
DIO |
- | - | - | - | - | - | - | - | - | - | - | - | - |
DPO |
- | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Cycle |
- | - | - | - | - | - | - | - | - | - | - | - | - |
Cash Conversion Cycle |
- | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Financial Ratios Neoleukin Therapeutics
| 2024-Q2 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
-1.09 | - | -0.41 | -26.68 | -0.26 | - | -1.18 | -0.28 | -0.28 | - | -0.28 | -0.27 | -0.27 | - | -0.04 | -0.2 | -0.18 | - | -2.26 | -0.09 | -0.09 | - | -0.64 | 0.12 | -0.62 | - | -0.5 | -0.59 | -0.36 | - | -0.46 | -0.63 | -0.39 | - | -0.43 | -0.44 | -0.6 | - | -0.59 | -0.51 | -1.28 | - | -15.64 | -7.89 | -8.48 | - | - | - | - | - | - | - | - |
EBITDA per Share |
-1.14 | - | - | -26.5 | -0.27 | - | -1.12 | -0.27 | -0.27 | - | -0.26 | -0.26 | -0.27 | - | -0.03 | -0.19 | -0.18 | - | -2.27 | -0.01 | - | - | -0.65 | 0.11 | - | - | -0.51 | -0.6 | - | - | - | - | - | - | - | - | - | - | - | 0.01 | 0.01 | - | 0.15 | 0.05 | 0.05 | - | - | - | - | - | - | - | - |
ROE % |
-16.95 | -16.46 | -28.83 | -35.19 | -55.65 | -37.62 | -47.59 | -45.19 | -40.80 | -27.38 | -28.56 | -19.76 | -15.80 | -10.79 | -52.53 | -93.08 | -87.99 | -43.29 | -63.92 | -42.82 | -38.81 | -36.74 | -48.70 | -40.04 | -57.98 | -34.30 | -39.93 | -33.59 | -27.21 | -17.81 | -22.45 | -21.46 | -18.31 | -14.94 | -32.32 | -45.06 | -55.69 | -44.09 | -38.96 | -16.45 | -0.21 | 7.90 | 7.90 | 2.77 | 1.54 | - | - | - | - | - | - | - | - |
ROA % |
-33.00 | -32.09 | -42.42 | -47.70 | -46.53 | -32.07 | -40.85 | -39.30 | -35.94 | -24.34 | -25.41 | -17.70 | -14.24 | -9.80 | -50.02 | -89.17 | -84.54 | -41.72 | -61.04 | -40.14 | -36.38 | -34.40 | -45.12 | -36.53 | -52.77 | -30.74 | -36.02 | -30.57 | -25.15 | -16.68 | -21.13 | -20.29 | -17.42 | -14.29 | -29.46 | -40.19 | -49.09 | -38.47 | -59.99 | -66.34 | -58.43 | -33.16 | -33.16 | -11.64 | -6.46 | - | - | - | - | - | - | - | - |
ROCE % |
-20.34 | -18.55 | -31.44 | -36.92 | -57.97 | -38.29 | -48.27 | -45.36 | -40.82 | -27.38 | -28.56 | -19.76 | -15.81 | -11.03 | -53.03 | -93.86 | -89.06 | -42.31 | -63.22 | -42.13 | -38.12 | -17.21 | -29.42 | -20.71 | -38.56 | -26.36 | -26.36 | -14.15 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Current Ratio |
7.2 | 6.1 | 6.2 | 6.5 | 5.8 | 5.4 | 6.0 | 6.8 | 7.8 | 8.0 | 8.3 | 9.4 | 9.5 | 10.9 | 10.9 | 10.9 | 10.9 | 27.6 | 27.6 | 27.6 | 27.6 | 15.7 | 15.7 | 15.7 | 15.7 | 9.6 | 9.6 | 9.6 | 9.6 | 15.9 | 15.9 | 15.9 | 15.9 | 23.0 | 23.0 | 23.0 | 23.0 | 7.8 | 7.8 | 7.8 | 7.8 | 2.1 | 2.1 | 2.1 | 2.1 | - | - | - | - | - | - | - | - |
DSO |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DIO |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DPO |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Cycle |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash Conversion Cycle |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency